Corral Javier, Parés David, García-Cuyás Francesc, Revollo Boris, Chamorro Ana, Lecumberri Carla, Tarrats Antoni, Castella Eva, Piñol Marta, Clotet Bonaventura, Videla Sebastià, Sirera Guillem
Department of General Surgery, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain.
Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain.
Pathogens. 2021 Feb 14;10(2):208. doi: 10.3390/pathogens10020208.
This single-center, retrospective cohort study sought to estimate the cumulative incidence in HIV-1-infected patients of biopsy-proven high-grade anal intraepithelial neoplasia (HGAIN) recurrence after infrared coagulation (IRC) treatment. The study was based on data from a prospectively compiled database of 665 HIV-1-infected outpatients who attended a hospital Clinical Proctology/HIV Unit between January 2012 and December 2015. Patient records were checked to see which ones had received IRC treatment but later experienced a recurrence of HGAIN. Cytology samples were also checked for the presence of human papilloma virus (HPV). A total of 81 of the 665 patients (12%, 95%CI: 10-15%), of whom 65 were men and 16 women, were diagnosed with HGAIN and again treated with IRC. Of these 81, 20 (25%) experienced recurrent HGAIN, this incidence being true of both men (16/65, 95%CI: 19-57%) and women (4/16, 95%CI: 10-50%). The median time to recurrence was 6 (2-19) months overall, 6 (2-19) months in men, and 4 (2-6) months in women. HPV infection was detected in all patients except two, with HPV-16 being the most common genotype. This rate of incidence of recurrent HGAIN following IRC treatment is consistent with other reports and highlights the importance of continued post-treatment surveillance, particularly in the first year.
这项单中心回顾性队列研究旨在评估经活检证实的高级别肛门上皮内瘤变(HGAIN)患者在接受红外凝固(IRC)治疗后复发的累积发生率。该研究基于一个前瞻性汇编数据库的数据,该数据库包含2012年1月至2015年12月期间在一家医院临床直肠病学/艾滋病科就诊的665名HIV-1感染门诊患者。检查患者记录,以确定哪些患者接受了IRC治疗,但后来出现了HGAIN复发。还检查了细胞学样本中是否存在人乳头瘤病毒(HPV)。665名患者中有81名(12%,95%CI:10-15%)被诊断为HGAIN并再次接受IRC治疗,其中65名男性,16名女性。在这81名患者中,20名(25%)出现HGAIN复发,男性(16/65,95%CI:19-57%)和女性(4/16,95%CI:10-50%)的复发率均如此。总体复发的中位时间为6(2-19)个月,男性为6(2-19)个月,女性为4(2-6)个月。除两名患者外,所有患者均检测到HPV感染,其中HPV-16是最常见的基因型。IRC治疗后HGAIN复发的发生率与其他报告一致,并突出了治疗后持续监测的重要性,尤其是在第一年。